Dobrzanski P - Search Results

1

Rapid induction in regenerating liver of RL/IF-1 (an I kappa B that inhibits NF-kappa B, RelB-p50, and c-Rel-p50) and PHF, a novel kappa B site-binding complex.

Tewari M, Dobrzanski P, Mohn KL, Cressman DE, Hsu JC, Bravo R, Taub R. Tewari M, et al. Among authors: dobrzanski p. Mol Cell Biol. 1992 Jun;12(6):2898-908. doi: 10.1128/mcb.12.6.2898-2908.1992. Mol Cell Biol. 1992. PMID: 1588976 Free PMC article.

2

RelB, a new Rel family transcription activator that can interact with p50-NF-kappa B.

Ryseck RP, Bull P, Takamiya M, Bours V, Siebenlist U, Dobrzanski P, Bravo R. Ryseck RP, et al. Among authors: dobrzanski p. Mol Cell Biol. 1992 Feb;12(2):674-84. doi: 10.1128/mcb.12.2.674-684.1992. Mol Cell Biol. 1992. PMID: 1732739 Free PMC article.

3

Differential interactions of Rel-NF-kappa B complexes with I kappa B alpha determine pools of constitutive and inducible NF-kappa B activity.

Dobrzanski P, Ryseck RP, Bravo R. Dobrzanski P, et al. EMBO J. 1994 Oct 3;13(19):4608-16. doi: 10.1002/j.1460-2075.1994.tb06782.x. EMBO J. 1994. PMID: 7925301 Free PMC article.

4

Both N- and C-terminal domains of RelB are required for full transactivation: role of the N-terminal leucine zipper-like motif.

Dobrzanski P, Ryseck RP, Bravo R. Dobrzanski P, et al. Mol Cell Biol. 1993 Mar;13(3):1572-82. doi: 10.1128/mcb.13.3.1572-1582.1993. Mol Cell Biol. 1993. PMID: 8441398 Free PMC article.

5

Specific inhibition of RelB/p52 transcriptional activity by the C-terminal domain of p100.

Dobrzanski P, Ryseck RP, Bravo R. Dobrzanski P, et al. Oncogene. 1995 Mar 2;10(5):1003-7. Oncogene. 1995. PMID: 7898917

6

The MLK family mediates c-Jun N-terminal kinase activation in neuronal apoptosis.

Xu Z, Maroney AC, Dobrzanski P, Kukekov NV, Greene LA. Xu Z, et al. Among authors: dobrzanski p. Mol Cell Biol. 2001 Jul;21(14):4713-24. doi: 10.1128/MCB.21.14.4713-4724.2001. Mol Cell Biol. 2001. PMID: 11416147 Free PMC article.

7

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders.

Hexner EO, Serdikoff C, Jan M, Swider CR, Robinson C, Yang S, Angeles T, Emerson SG, Carroll M, Ruggeri B, Dobrzanski P. Hexner EO, et al. Among authors: dobrzanski p. Blood. 2008 Jun 15;111(12):5663-71. doi: 10.1182/blood-2007-04-083402. Epub 2007 Nov 5. Blood. 2008. PMID: 17984313 Free PMC article.

8

CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis.

Bozyczko-Coyne D, O'Kane TM, Wu ZL, Dobrzanski P, Murthy S, Vaught JL, Scott RW. Bozyczko-Coyne D, et al. Among authors: dobrzanski p. J Neurochem. 2001 May;77(3):849-63. doi: 10.1046/j.1471-4159.2001.00294.x. J Neurochem. 2001. PMID: 11331414 Free article.

9

A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779.

Dugan BJ, Gingrich DE, Mesaros EF, Milkiewicz KL, Curry MA, Zulli AL, Dobrzanski P, Serdikoff C, Jan M, Angeles TS, Albom MS, Mason JL, Aimone LD, Meyer SL, Huang Z, Wells-Knecht KJ, Ator MA, Ruggeri BA, Dorsey BD. Dugan BJ, et al. Among authors: dobrzanski p. J Med Chem. 2012 Jun 14;55(11):5243-54. doi: 10.1021/jm300248q. Epub 2012 May 18. J Med Chem. 2012. PMID: 22594690

10

Antiangiogenic and antitumor efficacy of EphA2 receptor antagonist.

Dobrzanski P, Hunter K, Jones-Bolin S, Chang H, Robinson C, Pritchard S, Zhao H, Ruggeri B. Dobrzanski P, et al. Cancer Res. 2004 Feb 1;64(3):910-9. doi: 10.1158/0008-5472.can-3430-2. Cancer Res. 2004. PMID: 14871820

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

33 results

Search Page

Filters